MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

22.34
+0.35
+1.59%
Closed 17:43 09/21 EDT
OPEN
21.89
PREV CLOSE
21.99
HIGH
22.39
LOW
21.36
VOLUME
769.61K
TURNOVER
--
52 WEEK HIGH
22.60
52 WEEK LOW
4.140
MARKET CAP
2.01B
P/E (TTM)
-7.8273
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
* Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women * Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual EventBASEL, Switzerland, Sept. 14,
GlobeNewswire · 09/14 13:30
Myovant Sciences Presents Additional Data On Bone Mineral Density In Women With Uterine Fibroids From Phase 3 LIBERTY Program And From Prospective Observational Study
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study Relugolix combination therapy maintained bone
Benzinga · 09/14 12:31
Is Myovant Sciences' (NYSE:MYOV) 152% Share Price Increase Well Justified?
Simply Wall St. · 08/20 18:03
Clovis Rubraca Data, And Other News: The Good, Bad And Ugly Of Biopharma
Clovis reports positive data from TRITON clinical trial.Interpace Biosciences sinks on potential compliance roadblocks.Myovant reports FDA acceptance of Uterine Fibroids drug application.
Seekingalpha · 08/18 15:52
Myovant Sciences shares are trading higher after the company announced that the FDA accepted its new drug application for a once-daily Relugolix combination tablet for the Uterine Fibroids.
Benzinga · 08/17 17:48
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
GlobeNewswire · 08/17 13:30
FDA accepts Myovant application for relugolix for uterine fibroids
The FDA accepts for review Myovant Sciences' (MYOV) marketing application seeking approval of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment
Seekingalpha · 08/17 13:14
Myovant Sciences Announces FDA Acceptance Of New Drug Application For Once-Daily Relugolix Combination Tablet For Uterine Fibroids
BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for
Benzinga · 08/17 12:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYOV stock price target is 30.86 with a high estimate of 55.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 40.86M
% Owned: 45.33%
Shares Outstanding: 90.15M
TypeInstitutionsShares
Increased
19
9.60M
New
26
9.23M
Decreased
4
66.38K
Sold Out
3
1.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Chairman/Director
Myrtle Potter
Chief Executive Officer/Director
Lynn Seely
Chief Financial Officer/Chief Accounting Officer
Frank Karbe
General Counsel/Secretary
Matthew Lang
Other/Director
Adele Gulfo
Other
Juan Camilo Arjona Ferreira
Lead Director/Independent Director
Kathleen Sebelius
Other
Kim Sablich
Director
Hiroshi Nomura
Independent Director
Terrie Curran
Independent Director
Mark Guinan
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More

Analyst Price Target

The average MYOV stock price target is 30.86 with a high estimate of 55.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MYOV
Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOV stock methods without spending real money on the virtual paper trading platform.